Skip to main content
. Author manuscript; available in PMC: 2013 Apr 15.
Published in final edited form as: Cancer Res. 2012 Feb 24;72(8):1986–1995. doi: 10.1158/0008-5472.CAN-11-3246

Figure 3. Therapeutic effects of ACT/TriVax against advanced B16 tumors.

Figure 3

(A) B6 s.c. mice (5/group) were injected with 5 × 105 B16 cells, and on day 12 received 1 × 106 Pmel-1 cells followed by TriVax on day 13 (arrow) and PD1 blockade or IL2Cx. P values were calculated using two-way ANOVA. * = 4/5 mice rejected their tumors. (B) Antigen-specific CD8 T cells evaluated by tetramer analysis on day 25 using blood samples. Points, value for each mouse; horizontal lines, averages of the group. P values were calculated with unpaired Student's t tests.